Eupraxia reports new odynophagia data from Phase 1b/2a RESOLVE trial in EoE
The company said swallowing pain and difficulty both dropped substantially in a subset of patients through 52 weeks, with no serious safety signals reported.
Eupraxia Pharmaceuticals announced on August 13, 2026 new results from its ongoing Phase 1b/2a RESOLVE trial of EP-104GI, marking the first analysis of the drug's effect on odynophagia, or pain when swallowing, in patients with eosinophilic esophagitis (EoE)1.
In patients from Cohorts 7 through 9, who received 20 injections of EP-104GI totaling 80 mg to 160 mg1, results showed that at baseline 62% of patients reported either moderate or severe odynophagia, falling to 31% at 2, 4, 8 and 12 weeks post treatment, and to 25% at 24, 36 and 52 weeks. At baseline, 15% of patients recorded no odynophagia, while at 52 weeks 50% recorded no odynophagia1.
For dysphagia, or difficulty swallowing, in the same cohorts, 77% of patients reported moderate or severe dysphagia at baseline, dropping to 54% at 12 weeks and to only 25% at both 24 and 52 weeks1.
On safety, the company said across both portions of the Phase 1b/2 RESOLVE trial, more than 130 patients have been treated with EP-104GI or placebo across over 2,000 individual injection sites, with no treatment-emergent or procedure-related serious adverse events observed, and no concerns regarding mean glucose or cortisol levels1.
Eupraxia described the Phase 1b/2a portion as a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with a history of confirmed active EoE1. Dosing is given as a single dose delivered through 4 to 20 injections into the esophageal wall, with dose escalation adjusting either the amount per injection site or the total number of sites1.
The company noted that its Phase 2b portion of RESOLVE, a randomized placebo-controlled study, is currently recruiting patients at the 120mg (20x6mg) and 160mg (20x8mg) dose levels, with interim data expected in the fourth quarter of 20261. Eupraxia also said it plans to release additional data from the open-label Phase 1b/2a portion of RESOLVE in the coming months1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.